Bone morphogenetic protein receptor inhibitors suppress the growth of glioblastoma cells

Kaye, Joel; Mondal, Arindam; Foty, Ramsey A.; Jia, Dongxuan; Langenfeld, John

doi:10.1007/s11010-022-04383-7

Cited by 6 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeted therapy inhibits tumor stem cells by cutting off tumor stem cell conduction pathways, attacking tumor stem cell surface markers, or inducing tumor stem cell differentiation, which opens up new research directions for radical tumor treatment. At present, there are mainly the following targeted treatment pathways, which weaken the self‐renewal ability of CSCs, 11 destroy the microenvironment of CSCs, 12 target the surface labeling molecules of CSCs, 13 enhance the sensitivity of CSCs to radiotherapy and chemotherapy, 14 and promote the differentiation of CSCs 15 . Our study aimed to target the surface labeling molecule of CD20+ melanoma tumor stem cells.…”

Section: Discussionmentioning

confidence: 99%

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells

Chen

Jiang

2022

Skin Research and Technology

View full text Add to dashboard Cite

Background Targeting CD20+ melanoma cancer stem cells (CSCs) subset is essential for treating melanoma. Anti‐CD20 aptamer‐modified exosomes (ACEXO) loaded with Adriamycin could be a therapeutic strategy for targeting CSCs. Materials and methods Exosomes loaded with Adriamycin were modified with anti‐CD20 aptamer and characterized by size and molecular markers using transmission electron microscope and dynamic light scattering. The uptake of ACEXO into CD20+ cells was checked, and its cytotoxicities in CD20+ melanoma cells, HEK 293T, and 3T3 cells were evaluated. At the same time, the in vivo distribution of ACEXO in the tumor‐bearing mice model was determined. Results The particle size of the exosome is about 80–100 nm. Western blot analysis showed that they expressed the characteristic exosome markers: CD9 and CD63. Quantitative analysis of the mean fluorescence intensity after 4 h incubation showed that ACEXO significantly improved Adriamycin uptake. Notably, the ACEXO killed only CD20+ melanoma cells. In addition, they exhibited good biocompatibility with both 293T and 3T3 cells at all doses. After intravenous injection, exosome distribution data showed that ACEXO's accumulation in the tumor is higher than anti‐CD20‐modified exosomes (AEXO)’s at all time points, and the accumulation increased as time prolonged. Addition of ACEXO reduces the number of tumorspheres in A375 or WM266‐4 cells compared to untreated controls or AEXO‐treated group. More important, while treating melanoma tumor‐bearing mice, ACEXO‐treated group showed the lowest tumor weight without body weight loss. Conclusion ACEXO loaded with Adriamycin could suppress tumor cell growth in vitro and in vivo, probably by targeting CD20+ melanoma CSCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells

Chen

Jiang

2022

Skin Research and Technology

View full text Add to dashboard Cite

show abstract

Section: Targeting Bmp Signaling Pathway In Gbmmentioning

confidence: 99%

“…In the contrast to the aforementioned therapeutic strategy to induce BMP signaling to initiate differentiation of GSCs, most recently, Kaye and co-workers showed that inhibition of BMP signaling could also have potential therapeutic relevance for fighting GBM [ 342 ]. In this study, BMP receptor inhibitors, DMH1, JL5, and Ym155 significantly decreased the expression of the inhibitor of differentiation protein 1 (ID1) in GBM cell lines [ 342 ]. The members of the ID family of protein, are co-expressed in diverse cell populations of GBM and conditional deletion of ID1 , ID2 and ID3 alleles suppressed the GBM tumor growth and diminished the population of GSCs (reviewed in [ 343 ]).…”

Section: Targeting Bmp Signaling Pathway In Gbmmentioning

confidence: 99%

“…Furthermore, Kaye and co-workers demonstrated that spheres formed from GBM cell lines after BMP4 treatment were smaller in size and number. However, treatment with JL5 completely prevented the formation of spheres, suggesting that inhibition of BMP signaling suppressed self-renewal more than its activation [ 342 ].…”

Section: Targeting Bmp Signaling Pathway In Gbmmentioning

confidence: 99%

“…It is important to point out that targeting the same signaling pathway in GSCs and GBM tumor cells can affect diverse sets of target genes and, consequently, different cellular processes. Kaye and co-workers recently demonstrated that both activation and suppression of the BMP signaling pathway had a negative effect on tumor sphere growth by affecting different targets [ 342 ]. Thus, there is a constant requirement for further laboratory and clinical research to investigate the mechanisms of receptor signaling downstream pathways in GSCs and GBM tumor cells.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 2 more Smart Citations

Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

Drakulić

Schwirtlich

Petrović

et al. 2022

Cells

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 months. Thus, there is an urgent need for new insights into GBM molecular characteristics and progress in targeted therapy in order to improve clinical outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies.

show abstract

Signaling pathways governing glioma cancer stem cells behavior

Nasrolahi

Azizidoost

Radoszkiewicz

et al. 2023

Cellular Signalling

View full text Add to dashboard Cite

Bone morphogenetic protein receptor inhibitors suppress the growth of glioblastoma cells

Cited by 6 publications

References 53 publications

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells

Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

Signaling pathways governing glioma cancer stem cells behavior

Contact Info

Product

Resources

About